Agios Pharmaceuticals, Inc. (AGIO)
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Agios Pharmaceuticals, Inc. (“Agios” or “the Company”) (NASDAQ: AGIO). Investors who purchased Agios securities are encouraged to obtain additional information and assist the investigation.
The investigation concerns whether Agios has violated federal securities laws.
Investigation Details
On September 4, 2025, Agios issued a press release “announc[ing] that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) goal date for the supplemental New Drug Application (sNDA) of PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, for the treatment of adult patients with non-transfusion-dependent (NTD) and transfusion-dependent (TD) alpha- or beta-thalassemia by three months to December 7, 2025.” On news of the delayed review, Agios’s stock price fell $4.48 per share, or 11.03%, to close at $36.13 per share on September 4, 2025.
What’s Next?
If you are aware of any facts relating to this investigation or purchased Agios securities, you can assist this investigation. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 332-239-2660
There is No Cost to You
We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys’ fees, usually a percentage of the total recovery, only if we are successful.
Why Bronstein, Gewirtz & Grossman
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
Attorney advertising. Prior results do not guarantee similar outcomes.
Contact
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Nathan Miller
332-239-2660 | [email protected]